Curated News
By: NewsRamp Editorial Staff
October 07, 2026
Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial
TLDR
- Quantum BioPharma's Lucid-MS offers a first-mover advantage by targeting myelin repair, potentially capturing the MS market with a novel mechanism.
- Quantum BioPharma's Lucid-MS phase 2 trial with Thermo Fisher will test a neuroprotective approach that targets demyelination instead of immune modulation.
- Quantum BioPharma's partnership aims to bring a new MS therapy that protects nerves, potentially improving quality of life for millions worldwide.
- Quantum BioPharma's Lucid-MS takes a fresh angle on MS by shielding nerve insulation, a departure from standard immune-suppressing drugs.
Impact - Why it Matters
This news matters because it signals a potential shift in how multiple sclerosis is treated. Current therapies primarily suppress the immune system, which can leave patients vulnerable to infections and may not address the underlying nerve damage. If Lucid-MS succeeds in Phase 2 trials, it could become the first therapy to directly protect myelin, offering new hope for halting or reversing disability. The involvement of Thermo Fisher’s clinical research business adds significant credibility and operational expertise, increasing the likelihood of a well-executed trial. For investors, this de-risks the development path and highlights Quantum BioPharma’s innovative pipeline. For patients, it represents a novel mechanism that could one day transform MS care from immune modulation to true neuroprotection, potentially improving quality of life and long-term outcomes.
Summary
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has taken a major step forward in its mission to treat multiple sclerosis (MS) with a novel approach. The company has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement the Phase 2 trial of Lucid-MS, its lead drug candidate for MS. This agreement transitions the innovative treatment from planning into execution, marking a critical milestone for Quantum and the MS community.
Unlike most MS drugs that work by quieting the immune system, Lucid-MS is designed around a proprietary platform that targets demyelination—the damage to the nerve’s protective insulation—rather than solely modulating the immune response. This neuroprotective strategy aims to preserve nerve function and potentially slow disease progression. Thermo Fisher’s clinical research business, a leading global contract research organization with deep expertise in central nervous system and MS studies, will oversee the trial’s implementation, bringing rigorous clinical validation to the program.
Investors and patients can follow the latest updates on QNTM in the company’s newsroom. The partnership underscores a growing interest in neuroprotective therapies for MS, which affects millions worldwide. By advancing Lucid-MS into Phase 2 testing, Quantum BioPharma is positioning itself at the forefront of a new treatment paradigm that could complement or even surpass existing immunomodulatory approaches. For more details, read the full announcement on Read More.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma Taps Thermo Fisher for Phase 2 Lucid-MS Trial
